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Abstract
Background: The acute-phase increase in serum C-reactive protein (CRP) is used to diagnose and monitor infectious and
inflammatory diseases. Little is known about the influence of genetics on acute-phase CRP, particularly in patients with
chronic inflammation.
Methods and Findings: We studied two independent sets of patients with chronic inflammation due to rheumatoid arthritis
(total 695 patients). A tagSNP approach captured common variation at the CRP locus and the relationship between
genotype and serum CRP was explored by linear modelling. Erythrocyte sedimentation rate (ESR) was incorporated as an
independent marker of inflammation to adjust for the varying levels of inflammatory disease activity between patients.
Common genetic variants at the CRP locus were associated with acute-phase serum CRP (for the most associated haplotype:
p=0.002, p,0.0005, p,0.0005 in patient sets 1, 2, and the combined sets, respectively), translating into an approximately
3.5-fold change in expected serum CRP concentrations between carriers of two common CRP haplotypes. For example,
when ESR=50 mm/h the expected geometric mean CRP (95% confidence interval) concentration was 43.1 mg/l (32.1–50.0)
for haplotype 1 and 14.2 mg/l (9.5–23.2) for haplotype 4.
Conclusions: Our findings raise questions about the interpretation of acute-phase serum CRP. In particular, failure to take
into account the potential for genetic effects may result in the inappropriate reassurance or suboptimal treatment of
patients simply because they carry low-CRP–associated genetic variants. CRP is increasingly being incorporated into clinical
algorithms to compare disease activity between patients and to predict future clinical events: our findings impact on the
use of these algorithms. For example, where access to effective, but expensive, biological therapies in rheumatoid arthritis is
rationed on the basis of a DAS28-CRP clinical activity score, then two patients with identical underlying disease severity
could be given, or denied, treatment on the basis of CRP genotype alone. The accuracy and utility of these algorithms might
be improved by using a genetically adjusted CRP measurement.
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Citation: Rhodes B, Merriman ME, Harrison A, Nissen MJ, Smith M, et al. (2010) A Genetic Association Study of Serum Acute-Phase C-Reactive Protein Levels in
Rheumatoid Arthritis: Implications for Clinical Interpretation. PLoS Med 7(9): e1000341. doi:10.1371/journal.pmed.1000341
Academic Editor: Aroon Hingorani, University of London, United Kingdom
Received March 16, 2010; Accepted August 12, 2010; Published September 21, 2010
Copyright:  2010 Rhodes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by an Arthritis Research UK (http://www.arthritisresearchuk.org) fellowship awarded to Benjamin Rhodes (grant number 18544).
The Health Research Council of New Zealand (http://www.hrc.gov.nz) funded the collection of New Zealand patients. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate
* E-mail: t.vyse@imperial.ac.uk
PLoS Medicine | www.plosmedicine.org 1 September 2010 | Volume 7 | Issue 9 | e1000341Introduction
Genetic variants at the CRP locus influence the low, basal levels
of serum C-reactive protein (CRP) in apparently healthy
individuals [1–5]. The primary motivation for these existing
studies has been the observation of a strong correlation between
basal CRP and future cardiovascular risk, and the possibility, now
looking less likely, that CRP has a causal role in this process [6,7].
The widespread clinical application of CRP measurement,
however, is not related to its low-level variation within the basal
range, but to the high levels seen as part of the human acute-phase
response. Serum CRP levels greater than 10 mg/l are generally
considered indicative of an infectious or inflammatory process [8].
CRP expression increases rapidly following an inflammatory
stimulus, leading to serum levels that may exceed 500 times
baseline, making CRP an ideal marker for the diagnosis and
monitoring of inflammatory processes. Serum CRP is extensively
used in all medical specialities for this purpose [8]. Surprisingly,
there has been little published data on the role of CRP variants in
determining the magnitude of this acute-phase response, and none
in the context of chronic active inflammation.
The demonstration of a strong, genetically determined and
hence lifelong, influence on the magnitude of acute-phase CRP in
any particular patient would have a number of important
implications. Firstly, as a diagnostic test, CRP thresholds are used
not only as a component of formal clinical algorithms, but also as
part of a physician’s intuitive decision-making process when
diagnosing inflammatory disease and making treatment decisions.
As we discuss later, this raises the possibility that false reassurance
could be given to a patient with disease, or optimal treatment
withheld, because they are genetically predisposed to only a
modest rise in acute-phase CRP. Secondly the demonstration of a
strong genetic effect on the acute-phase CRP response also raises
the possibility that this may have consequences in terms of
individual susceptibility to diseases in which the innate immune
system plays a protective (or deleterious) role.
The existing literature on the effects of CRP genetics on acute-
phase CRP levels consists of five studies, each of which measured
the magnitude of CRP rise following a single noxious stimulus [9–
13]. As we discuss later, this approach may be complicated by the
difficulty in quantifying or standardising stimuli between patients
or a difficulty in inducing a marked CRP rise. We have therefore
taken a different approach, which we believe offers distinct
advantages. We have studied genetic determinants of acute-phase
CRP in patients with rheumatoid arthritis, a chronic inflammatory
disease characterised by a marked acute-phase response.
By studying patients with rheumatoid arthritis we made use of
the historical tendency to record the erythrocyte sedimentation
rate (ESR) alongside CRP as an alternative and independent
marker of inflammation. Although ESR has become less widely
used because of its slow response following an inflammatory
stimulus, this is not important in chronic inflammation where both
CRP and ESR are at a steady state. The factors contributing to
ESR are not fully understood, but seem to be related to intrinsic
erythrocyte membrane properties, notably the charge, with a lesser
influence from the concentration of large plasma proteins such as
immunoglobulin or fibrinogen [14,15]. There is no evidence that
serum CRP levels directly influence ESR: indeed the slow
fluctuation in ESR following the onset or resolution of inflamma-
tion is in stark contrast to the rapid expression and short half-life of
CRP [8,16,17]. The incorporation of ESR as a covariate in our
model fulfils two purposes. First, it provides an independent
adjustment for the underlying inflammatory status of each of our
patients (a consequence of their synovial joint inflammation).
Without this adjustment, the random error associated with
dramatically differing levels of inflammation across the cohort
(random with respect to either recruitment into the study, or with
respect to underlying CRP genotype) may be so great as to make
the relatively small effect of CRP genotype on CRP levels difficult
to demonstrate with any level of significance. Second, since most
physicians have an intuitive appreciation of the relationship
between CRP and ESR in a variety of inflammatory settings, the
incorporation of ESR into our models allows us to generate a
clinically interpretable estimate of the magnitude of genetic effect
at all levels of underlying inflammatory drive. Our results are
therefore directly relevant to the conditions in which CRP
quantification contributes to clinical decision making.
In this paper we study the association between genetic variants
at the CRP locus and acute-phase CRP in patients with chronic
active inflammation due to rheumatoid arthritis.
Methods
Study Participants
The discovery study was carried out in a cohort of 281 UK
rheumatoid arthritis cases (patient set 1). Details on the
recruitment of these patients have been published elsewhere
[18]. The mean age of participants was 61 y (SD 12), 79% were
female. Replication was performed in 414 rheumatoid arthritis
patients recruited in New Zealand (Wellington and Christchurch)
and Australia (Adelaide) (patient set 2). The mean age was 62 y
(SD 13) and 70% were female. All patients were of self-reported
white European ancestry and met 1987 ACR revised criteria for
the diagnosis of rheumatoid arthritis [19]. Data were available for
at least one pair of measurements for CRP and ESR (Westergren
method) collected simultaneously as part of routine clinical
management. For some of the individuals in patient set 2, data
were available for serial CRP/ESR pairs, measured at different
times. For these individuals, each CRP/ESR pair was arbitrarily
assigned an integer value, and a random number generator used to
identify one of these pairs at random to carry forward for analysis.
Ethical approval for the collection of DNA and patient data was
obtained locally at each recruitment site (from the Guy’s hospital
Research Ethics Committee, London UK, the University Hospital
Lewisham ethics committee, London, UK, the Upper South B
regional ethics committee of New Zealand, the MultiRegion
Ethics committee of New Zealand, and the Research and Ethics
committee, Repatriation General Hospital, Adelaide Australia).
Written informed consent was obtained from each patient. Patient
identity was encrypted at the site of collection and all data were
analysed anonymously.
SNP Selection and Genotyping
SNPs were selected to tag common variation at CRP. We used
previously published genotype data on 22 SNPs densely covering
CRP in 799 unrelated, healthy UK individuals as our reference
dataset for this population [20]. Using these data in turn captured
all of the CRP variation observed in the HapMap CEPH
population. Tagging SNPs were selected using the tagger facility
of Haploview (employing an aggressive tagging strategy, r
2=0.9
threshold) [21].
Genotyping on patient set 1 was performed by matrix-assisted
laser desorption and ionization-time of flight (MALDI-TOF) mass
spectrometry (Sequenom) using the iPLEX assay. Genotyping on
patient set 2 was outsourced to Kbioscience Ltd using their variant
of competitive allele-specific PCR (KASPar) (www.kbioscience.co.
uk/chemistry/chemistry_application_note.html). Duplicate geno-
typing was performed on 5% of patients to ensure reproducibility
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sion criteria were: any individual genotyped at ,90% of markers,
any marker genotyping in ,90% individuals, any marker with a
minor allele frequency ,5%, and any marker out of Hardy-
Weinberg equilibrium (p,0.01). Ten individuals were excluded
from patient set 2 because of poor genotyping, otherwise
genotyping quality control criteria were met and all markers were
in Hardy-Weinberg equilibrium. Population haplotype structure
was inferred using Haploview, and individual patient haplotypes
were inferred using PHASE v. 2.1 [21,22]. Only individuals for
whom haplotypes could be assigned with a posterior probability
.0.95 were carried forward for haplotype association analysis. Six
individuals were excluded after failing to meet this requirement.
Statistical Analysis
The standard CRP assay becomes nonlinear below 1 mg/l
leading to the common practice of reporting values as a range (i.e.,
,1) or rounded to an integer (i.e., ‘‘0’’). We assigned all CRP
measurements reported as ,1 mg/l a value of 0.5 mg/l. An initial
review identified four data outliers with very low ESR but
increased CRP; three from patient set 1 and one from patient set
2. We postulated that these individuals were in the early stages of
an acute inflammatory episode (when the rise in ESR lags behind
the rise in CRP) and excluded them from further analysis.
Both CRP and ESR distributions were positively skewed so a
log-transformation was applied for analysis. The association
between SNP genotype and the quantitative markers of inflam-
mation (CRP or ESR) was evaluated by linear model, with
genotype modelled as an additive allelic effect. All parameter
estimates given throughout the paper are expressed relative to the
major allele. An initial assessment was made of the association
between CRP SNPs and the ‘‘raw’’ serum CRP levels, unadjusted
for ESR. In addition, the direct association between CRP SNPs
and ESR itself was made. In all subsequent models the association
between CRP genotype (either at SNP or haplotype level) was
assessed with ESR, as an independent marker of background
inflammatory status, included as a covariate in the model. The
relationship between CRP and ESR was nonlinear, so the final
model included a significant quadratic term:
logCRP~b0z b1|logESR ðÞ z b2|logESR2 
z b3|genotype ðÞ zerror:
Since patients and data in this study originated from four sites of
collection (South London, Wellington, Christchurch, and Ade-
laide), a random effects parameter was included where relevant to
reflect these clusters of data.
In the haplotype analyses, a comparison of haplotype effect was
achieved by simultaneously entering each haplotype into the
model with the remaining, commonest, haplotype (H1) acting as
the reference. Expected CRP values were derived from the
regression parameters by back-transforming to the original scale,
with the mean of the log-distribution reflecting the median of the
untransformed distribution.
Results
In patient set 1 the median serum CRP was 11 mg/l (range 1–
195; 5th, 95th centiles 5, 88). 51.8% of CRP measurements were
.10 mg/l. The median ESR was 22.5 mm/h (range 2–132; 5th,
95th centiles 4, 83). The six genotyped SNPs (with minor allele
frequency) were rs2808632 (0.28), rs3093059 (0.07), rs1800947
(0.08), rs1205 (0.35), rs876538 (0.23), and rs11265257 (0.40). In a
preliminary analysis, unadjusted for background inflammatory
status (ESR), significant associations between serum CRP and
SNPs rs1205, rs11265257, and rs1800947 were observed (Tables
S1 and S2). In contrast, ESR was not associated with any CRP
SNP (Table S3).
Table 1 shows the association of CRP SNPs with serum CRP
level, incorporating ESR as a covariate to adjust for the underlying
inflammatory status of that individual. A conservative Bonferroni
correction for six tests would require p,0.008 to achieve overall
significance, hence both rs1205 and rs1125257 are strongly
associated with CRP, with the minor allele associated with lower
CRP level. We looked for departure from a simple additive model
of allele effect but none was seen.
In patient set 2 the median CRP was 5 mg/l (range 0.25–334;
5th, 95th centiles 0.25, 60). 34.9% of CRP measurements were
.10 mg/l. The median ESR was 16 mm/h (range 2–106; 5th,
95th centiles 4, 58). Overall, the level of inflammation observed in
the patients in set 2 was therefore slightly less than that observed in
set 1, suggesting either less severe disease or better disease control;
this does not impact on the interpretation of our findings. The
SNP minor allele frequencies were rs2808632 (0.34), rs3093059
(0.05), rs1800947 (0.07), rs1205 (0.34), rs876538 (0.24), and
rs11265257 (0.41). Initial analysis of patient set 2 confirmed the
association of CRP genotype with ‘‘raw’’ serum CRP levels, but not
with ESR (Tables S1–S3). Table 1 demonstrates the replication in
patient set 2 of the significant association of rs1205 and
rs11265257 with ESR-adjusted serum CRP. It also shows strong
association for rs1800947, a more rare SNP with only borderline
association in patient set 1.
Having replicated the initial genetic associations, we performed
a combined analysis using pooled data from both cohorts. In
addition to the inclusion of a ‘‘cohort’’ term in our combined
Table 1. Single CRP SNP effects on acute-phase serum CRP.
SNP Discovery Cohort (Patient Set 1) Replication Cohort (Patient Set 2) Combined Cohorts
b (logCRP) 95% CI p-Value b (logCRP) 95% CI p-Value b (logCRP) 95% CI p-Value
rs2808632 20.004 20.070 to 0.062 0.906 20.026 20.098 to 0.045 0.473 20.017 20.070 to 0.035 0.522
rs3093059 0.122 0.011 to 0.232 0.031 20.003 20.162 to 0.155 0.967 0.047 20.057 to 0.151 0.372
rs1800947 20.095 20.195 to 0.005 0.062 20.273 20.406 to 20.140 ,0.0005 20.169 20.259 to 20.078 ,0.0005
rs1205 20.095 20.155 to 20.035 0.002 20.116 20.188 to 20.045 0.001 20.109 20.159 to 20.058 ,0.0005
rs876538 0.000 20.069 to 0.070 0.991 20.038 20.118 to 0.043 0.360 20.026 20.083 to 0.032 0.382
rs11265257 20.096 20.155 to 20.037 0.001 20.114 20.185 to 20.044 0.002 20.106 20.157 to 20.056 ,0.0005
doi:10.1371/journal.pmed.1000341.t001
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potential SNP 6 cohort interactions that might complicate the
interpretation of this analysis. None of the key SNP effects we
observed differed significantly from one cohort to another. This
combined analysis again emphasised the high level of significance
attached to our identified SNPs (Table 1).
While Table 1 shows the highly significant associations between
SNPs at CRP and serum CRP level, it does not provide easily
interpretable parameter estimates. In Table 2 we have therefore
shown the geometric mean and 95% confidence intervals (CIs)
modelled for each genotype (with reference to the major allele
homozygotes) at the associated SNPs, in our combined dataset. It
should be reiterated that the geometric mean of the log-
transformed CRP distribution can be considered equivalent to
the median of the untransformed CRP distribution. Since the
predicted CRP levels depend on the background inflammatory
status (as assessed by ESR) in this model, we have illustrated
expected geometric mean CRP at two levels of background
inflammation (ESR 40 mm/h and ESR 80 mm/h).
Considerable evidence, from the basal CRP literature, supports
the hypothesis that there are multiple functional SNPs at the CRP
locus [23–25]. We tested this hypothesis directly in the combined
dataset by performing an analysis conditioned on the most
significant SNPs and were able to demonstrate an independent
association from three SNPs entered simultaneously into the
regression model (Table S4). It is therefore evident that an analysis
of the effect of CRP genotype on serum CRP based on individual
SNPs alone is likely to markedly underestimate the overall effect
size. We therefore performed a haplotype analysis. This approach
has the advantage of providing a realistic estimate of the integrated
effect of multiple SNPs on acute-phase serum CRP levels, while
also only considering those SNP combinations that are actually
found in the population and are of direct clinical relevance.
Table 3 demonstrates the inferred haplotype structure and
haplotype frequencies in the two patient sets. Table 4 demonstrates
the association of CRP haplotypes with serum CRP level, with
reference to the commonest haplotype, H1, which is set as the baseline.
Once again, individual haplotypes were consistently associated with
acute-phase serum CRP with high levels of significance in both patient
sets individually and in a combined analysis.
Regression parameters were used to illustrate expected CRP
values depending on background inflammatory status (defined this
by ESR) and CRP haplotype. In the setting of chronic
inflammation we would expect both ESR and CRP to be at
steady state and in equilibrium. Figure 1A illustrates the expected
geometric mean (median) CRP (95% CI) for individuals
homozygous for haplotype H1 compared with the expected
median for H4 homozygotes. H1 homozygotes have a median
CRP 232% higher than H4 homozygotes at each level of
inflammation (p,0.0005).
The percentage of the population carrying any specific
haplotype pair is modest (7% for H1 homozygotes and 1% for
H4 homozygotes), so we illustrate that the effect on CRP level is
not confined solely to rare haplotype pairs but can also be
demonstrated between larger groupings in the population. In
Figure 1B, we have compared individuals carrying any combina-
tion of the H1 or H5 haplotypes (i.e., H1 H1, H1 H5, or H5 H5),
with individuals carrying any combination of the remaining
haplotypes. The H1/H5 group, constituting 11% of the
population have an acute-phase CRP 82% higher than the 45%
of individuals carrying two of the remaining haplotypes
(p,0.0005). Individuals with one haplotype from each of these
two groups will naturally have a CRP level falling somewhere in
the middle.
We have observed that the magnitude of CRP haplotypic effect
on serum CRP, over and above the variation in CRP expected due
to underlying inflammatory status, is therefore large. To exclude
the possibility that these observations were being unduly
influenced by rare data outliers we performed additional analyses.
Firstly we reran the model after excluding the 5% of individuals
with the highest or lowest overall CRP levels. No meaningful
changes to the observed significance levels or parameter estimates
were observed (Table S5). Secondly we assessed the impact of
individuals to the model by their Cook’s distances. All Cook’s
distances were ,1, and in addition an exclusion of the 5% of
individuals with the greatest Cook’s distance again resulted in no
material change to the overall effect sizes and significance levels
(Table S6).
Discussion
Summary and Comparison with Current Literature
We have shown a highly significant association between CRP
genotype and acute-phase serum CRP level, and to our knowledge
we are the first to demonstrate this in a group of patients that
includes a considerable number with chronic active inflammation
(40% have serum CRP .10 mg/l). We believe that the size of the
genetic effect we have observed is large enough to have a clinically
Table 2. CRP parameter estimates (geometric mean) from the combined cohorts.
SNP Genotype Genotype Frequency Parameters when ESR=40 Parameters when ESR=80
Geometric Mean
CRP (mg/l) 95% CI
Geometric Mean
CRP (mg/l) 95% CI
rs1800947 G G 0.85 26.1 ref 42.2 Ref.
G C 0.13 17.7 14.4–21.8 28.6 23.2–35.3
C C 0.01 12.0 7.9–18.2 19.4 12.8–29.5
rs1205 G G 0.43 28.2 Ref. 45.7 Ref.
G A 0.45 21.9 19.5–24.6 35.5 31.7–40.0
A A 0.12 17.0 13.5–21.6 27.6 22.0–35.0
rs11265257 G G 0.35 29.2 Ref. 47.6 Ref.
G A 0.50 22.9 20.4–25.7 37.3 33.1–41.8
A A 0.15 17.9 14.1–22.6 29.2 23.1–36.7
doi:10.1371/journal.pmed.1000341.t002
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which in turn may influence therapeutic decision making.
A key issue in the study of acute-phase CRP genetics is how to
quantify the level of inflammatory stimulus driving the acute-phase
response. Without this adjustment, random error introduced by
varying levels of inflammation across our study population may be
so large as to mask the genetic effects owing to variation at the CRP
locus. We explained in the introduction that we believe that the
incorporation of ESR into our analysis enables us to quantify the
background level of inflammation in the chronic inflammatory
setting. We hypothesized that there is no biological plausibility for
a causal link to underlie the normal CRP/ESR correlation. The
data from this study provide additional support for this
assumption, by showing no association between CRP polymor-
phisms and ESR, and therefore support the hypothesis that CRP
and ESR are highly correlated, but truly independent, markers of
inflammation.
The use of ESR allowed us to find, with high levels of
significance, SNPs and haplotypes associated with high and low
acute-phase CRP expression. Existing studies addressing this
question have all measured the magnitude of CRP rise following a
single noxious stimulus. The largest of these looked at the
postmyocardial infarction CRP rise and, like us, found higher
levels in carriers of the rare allele of rs3093059 and also the A allele
of rs3091244, which is on the same haplotype. Conversely lowest
CRP increases were seen in carriers of the rare alleles of rs1800947
and rs1205 and the haplotype (H4), which contains both of these
SNPs [12]. Other studies have found an association of rs1800947
with lower serum CRP after coronary artery bypass surgery and
after oesophagectomy, and rs1130864 with higher serum CRP
postcoronary artery bypass surgery [10,11,13]. All these studies
are complicated by the inability to reliably compare surgical
trauma from one procedure to another. Early studies also showed
an association between rs1130864 and CRP levels following
periodontal therapy and following strenuous exercise, but these
stimuli only elicited a low-grade acute-phase response [9,13]. The
findings reported in this study therefore confirm those of earlier
reports, but extend them to demonstrate highly significant genetic
effects on CRP levels in the setting of chronic inflammation.
In terms of the magnitude of the genetic effect, there is a great
deal of variability in the literature discussed above. For example in
the cardiac surgery study of Brull and colleagues individuals
homozygous for the common allele of rs1130864 had CRP levels
that were only 20% higher than heterozygotes or individuals
homozygous for the rare allele (164 versus 194 mg/l) [13]. In
contrast Suk et al., who examined the increase in CRP
concentration following myocardial infarction saw almost 600%
difference between genotypes associated with low and high CRP
concentrations (11 versus 77 mg/l) [12]. Much of this difference
can undoubtedly be explained by the SNP chosen for the study,
and also methodological issues such as the level of control for
underlying inflammatory stimulus. It is clear, however, that the
large effect of CRP genotypes that we have observed in this study
in the setting of chronic inflammation, is consistent with large
effects that have already been described following acute stimuli
(such as those described by Suk et al. [12].).
There is also consistency between the SNPs we find associated
with elevated CRP in chronic inflammation and those document-
ed in basal CRP studies. In particular both rs1205 and rs1800947
have been widely associated with lower basal CRP expression [2–
5]. Similar to the acute-phase literature, there is also variation in
the magnitude of genotype effects in basal CRP studies, ranging
from an approximate 50% difference to a difference of more than
500% in CRP concentrations between high and low CRP
associated genotypes, from study to study and depending on
which SNP or haplotype is examined [1,2,5]. It is possible,
therefore, that the effect we report in the setting of chronic
inflammation is simply an extension of the same effect that is
observed with basal CRP. This observation is of interest, because it
suggests that the low grade stimulation of CRP expression by
Table 3. CRP haplotype architecture and frequency.





H1 G G G G T A 0.29 0.26
H2 A G A G T A 0.27 0.27
H3 G A G G T C 0.22 0.24
H4 A G A C T A 0.08 0.07
H5 G G G G C A 0.06 0.05
doi:10.1371/journal.pmed.1000341.t003
Table 4. CRP haplotype effect on acute-phase serum CRP.
Haplotype Discovery Cohort Replication Cohort Combined Cohorts
b 95% CI p-Value b 95% CI p-Value b 95% CI p-Value
H1 Ref. — — Ref. — — Ref. — —
H2 20.053 20.096 to 20.009 0.018 20.254 20.403 to 20.105 0.001 20.144 20.209 to 20.079 ,0.0005
H3 20.033 0.080 to 20.014 0.172 20.250 20.396 to 20.104 0.001 20.105 20.173 to 20.038 0.002
H4 20.102 20.166 to 20.038 0.002 20.557 20.776 to 20.339 ,0.0005 20.261 20.359 to 20.162 ,0.0005
H5 0.032 20.038 to 0.101 0.372 20.106 20.366 to 0.154 0.423 20.044 20.066 to 0.154 0.431
doi:10.1371/journal.pmed.1000341.t004
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expression of CRP in response to classical inflammatory stimuli
[2,26].
Clinical Implications of the Data
By incorporating ESR we can use the model parameters to
calculate the expected median CRP for an individual carrying any
combination of CRP haplotype at any level of background
inflammation. This finding showed that the genetic associations
translated into marked and clinically relevant effects on acute-
phase CRP. Although serum CRP is interpreted as part of a
complete clinical picture, we propose that, for a newly symptom-
atic patient, a CRP of 9 mg/l would be reassuring and might
trigger a different clinical decision from a CRP of 30 mg/l;
similarly for a patient with known inflammatory disease a CRP of
15 mg/l may be observed, but a CRP of 50 mg/l is likely to
trigger a change in treatment; yet our data suggest that these CRP
differences could occur simply owing to genetics, independent of
any difference in underlying disease activity.
In addition to these intuitive examples, it is worth considering
specific clinical algorithms that incorporate CRP. For example,
rheumatoid arthritis disease activity is frequently assessed using the
Figure 1. Predicted acute-phase CRP level (95% CI), stratified by haplotype, and according to the ESR-defined level of background
inflammation. Annotated by the haplotype pair (A), or grouping (B), represented on the graph, with the population frequency of that combination.
Data from the combined cohorts.
doi:10.1371/journal.pmed.1000341.g001
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28 specific joints, a global assessment of disease activity by visual
analogue scale [VAS], and a biochemical marker of inflammation,
either ESR or CRP [http://www.reuma-nijmegen.nl/www.das-
score.nl/index.html]). In the United Kingdom a DAS-score
threshold is used to determine who receives funding for expensive
biological therapies. While the DAS28-ESR is more frequently
used at present, it seems inevitable that the DAS28-CRP will
increase in popularity, and this is where the effect of genetics
becomes important [27]. A patient with a genetically determined
CRP of 66 mg/l, six swollen and tender joints, and a VAS of
50 mm will have a DAS score of 5.24. A patient with a genetically
determined low acute-phase CRP of 20 mg/l, and an identical
VAS would require an additional five tender or ten swollen joints
to achieve this DAS score. In other words, a patient with
genetically determined low CRP would be required to have
considerably worse disease to be considered for the same
treatment as a patient with genetically determined high CRP.
A review of the recent literature reveals multiple studies
proposing a predictive value for acute-phase CRP; including the
prediction of all-cause hospital mortality, death and complications
in various critical care scenarios, cancer relapse, and the
progression of inflammatory arthritis [28–35]. Our data do not
contradict these study findings, but they suggest that in some
situations the predictive ability of CRP could be significantly
improved by the provision of a genetic adjustment. Ironically,
while CRP measurement offers many advantages over ESR, we
have demonstrated a potential drawback in that common genetic
variants strongly influence serum levels. In contrast ESR, which is
determined by a number of different physiological processes (as
discussed earlier), would seem less likely to be strongly influenced
by any individual genetic variant or locus (this, of course, remains
to be tested).
Although our study was conducted only in patients of white
European ancestry, a comparison with existing studies in different
ethnic groups raises the possibility of population differences in the
acute-phase CRP response, because of population differences in
the haplotype architecture at CRP. Of the trans-ethnic mapping
studies we are aware of, the most extreme difference appears to be
between African American and Filipino populations [36,37]. In
African Americans haplotypes tagged by the minor allele of
rs180097 (H4) are very rare (,1%), but in Filipinos this haplotype
is common (10%). Similarly haplotypes with the common allele of
rs1800974 but the rare allele of rs1205 (H2) are found on 16% of
African American but on 43% of Filipino chromosomes. Both
these haplotypes are associated with lower acute-phase CRP, and
it is intriguing to question whether this would translate into a
global tendency towards lower acute-phase CRP in Filipinos
compared with African Americans. This hypothesis clearly
requires experimental confirmation.
We would also like to speculate on the wider issue of whether
the magnitude of acute-phase CRP rise in response to inflamma-
tory stimuli has any implications for patients in terms of the
physiological or pathological response to disease. Producing more
CRP may offer benefits, perhaps by enhancing clearance of
pathogenic bacteria, or by enhancing the clearance of apoptotic
cells and reducing susceptibility to systemic autoimmunity [8].
However excessive CRP production may also have deleterious
consequences, by promoting inflammation and tissue damage in
unwanted situations. This finding has been demonstrated in a rat
model of myocardial infarction, where injection of human CRP is
associated with a poor outcome; a situation that can be reversed by
synthetic CRP inhibitors [23]. Whether naturally occurring,
genetically determined variation in the level of acute-phase
response translates into differing outcomes in these varied clinical
situations remains to be tested.
Study Limitations
We recognise the limitations to our study. There may be
considerable heterogeneity within our study populations, which
were recruited over four different sites, with CRP and ESR
quantified in four different laboratories. We recognise that
although patients self-reported white European ancestry, there
may be subtle differences in population ancestry, particularly
between patients recruited from the Northern and Southern
hemispheres, and that this has not been accounted for by a
principle components analysis. In addition we were unable to
account for variables such as medication history, which may be
important given the reported effect of drugs such as statins on
basal CRP levels.
Although our study aim was to assess the influence of genetics
on the acute-phase CRP response, we appreciate that 60% of our
study participants had a serum CRP concentration of #10 mg/l
and only 8% had very high serum concentration of CRP
(.50 mg/l). The recruitment of patients with uncontrolled
inflammation is of course difficult as these patients tend to be
aggressively treated.
As this study was conducted in patients with rheumatoid
arthritis we need to question whether or not our data can be
extrapolated to other chronic inflammatory diseases. CRP itself has
never been reported as a susceptibility gene in rheumatoid arthritis
and, although we did not perform a disease association study here,
the allele frequencies we observe in our patient sets are very close
to those widely reported elsewhere for non-rheumatoid arthritis
patients. We therefore have no reason to suppose that rheumatoid
arthritis is a ‘‘special case’’ in terms of its influence on the acute-
phase response. We would therefore hypothesize that our findings
can be extrapolated to other chronic inflammatory diseases.
Conclusion
CRP can be measured easily and standard assays offer great
accuracy. While the extreme sensitivity and rapid response to
changing levels of inflammation make CRP measurement an
invaluable clinical tool, our data introduce a note of caution.
Acute-phase CRP may be strongly influenced by common genetic
variants and CRP concentrations should therefore be interpreted
in light of this. If technology advances to the stage of allowing
rapid bedside genetic testing, then a personalised, genetically
adjusted CRP level may prove to be a useful diagnostic and
predictive biomarker.
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C-reactive protein (CRP) is a serum marker for inflammation or
infection and acts by binding to a chemical (phosphocholine)
found on the surfaceof dead or dying cells (and some types of
bacteria) in order to activate the immune system (via the
complement system). Fat cells release factors that stimulate
the liver to produce CRP, and serum levels greater than
10 mg/l are generally considered indicative of an infectious or
inflammatory process. After an inflammatory stimulus, serum
CRP levels may exceed 500 times baseline, so CRP is used in all
medical specialities to help diagnose inflammation and
infection. Although patients with chronic inflammatory
diseases, such as rheumatoid arthritis, have raised levels of
CRP, levels of CRP are still highly variable. Some studies have
suggested that there may be genetic variations of CRP (CRP
variants) that determine the magnitude of the acute-phase
CRP response, a finding that has important clinical implica-
tions: CRP thresholds are used as a diagnostic component of
formal clinical algorithms and play an important role in a
clinician’s decision-making process when diagnosing inflam-
matory disease and choosing treatment options. Therefore, it
is possible that false reassurance could be given to a patient
with disease, or optimal treatment withheld, because some
patients are genetically predisposed to have only a modest
increase in acute-phase CRP.
Why Was This Study Done? Although some studies have
looked at the CRP gene variant response, few, if any, studies
have examined the CRP gene variant response in the context
of chronic inflammation, such as in rheumatoid arthritis.
Therefore, this study aimed to determine whether CRP gene
variants could also influence CRP serum levels in rheumatoid
arthritis.
What Did the Researchers Do and Find? The authors
studied two independent sets of patients with chronic
inflammation due to rheumatoid arthritis (total 695 patients):
onepatientsetusedacohortof281patientsin theUK,andthe
other patient set (used for replication) consisted of 414
patients from New Zealand and Australia. A genetic technique
(a tagSNP approach) was used to capture common variations
at the CRP locus (haplotype association analysis) at both the
population and the individual level. The relationship between
genotype and serum CRP was explored by linear modeling.
The researchers found that common genetic variants at the
CRP locuswereassociatedwithacute-phaseserumCRPinboth
patient sets translating into an approximate 3.5-fold change in
expected serum CRP between carriers of two common CRP
variants. For example, when ESR=50 mm/h the expected CRP
serumlevelforonecommonCRPvariantwas43.1 mg/landfor
another CRP variant was 14.2 mg/l.
What Do These Findings Mean? Thefindings of thisstudy
raise questions about the interpretation of acute-phase serum
CRP, as they suggest that there is a significant associa-
tion between CRP variants and acute-phase serum CRP
concentrations in a group of patients with rheumatoid
arthritis, including those with chronic active inflammation.
The size of the genetic effect may be large enough to have a
clinically relevant impact on the assessment of inflammatory
disease activity, which in turn may influence therapeutic
decision making. Failure to take into account the potential for
genetic effects may result in the inappropriate reassurance or
undertreatment of patients simply because they carry low-
CRP–associated genetic variants. CRP is increasingly being
incorporated into clinical algorithms to compare disease
activity between patients and to predict future clinical events,
so these findings impact on the use of such algorithms. The
accuracyand utility of thesealgorithms might be improved by
using a genetically adjusted CRP measurement.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000341
N Lab Test Online provides information on CRP
N The Wellcome Trust provides a glossary of genetic terms
N Learn.Genetics provides access to the Genetic Science
Learning Center, which is part of the human genome
project
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